Article thumbnail

Biphasic insulin aspart 30/70 (BIAsp 30) in the treatment of type 1 and type 2 diabetes

By Paul Valensi

Abstract

The pharmacological advantages of the rapid-acting analog, insulin aspart, over human insulin have contributed to the widespread prescription of the premix, biphasic insulin aspart 30/70 (BIAsp 30), in type 1 (T1DM) and type 2 diabetes (T2DM). This article reviews the available literature on the pharmacology, efficacy and safety of BIAsp 30 in T1DM and T2DM from an online search of the PubMed database. Following injection, BIAsp 30 reaches higher plasma insulin levels more quickly than human premix or basal insulin, giving effective reduction of postprandial hyperglycemia. In T1DM patients, randomized controlled trials (RCTs) have shown that HbA1c reduction is similar, but postprandial glycemic control is better, with BIAsp 30 than with human insulin regimens. In T2DM patients, lowering of HbA1c and postprandial hyperglycemia with BIAsp 30 compare favorably with optimized oral antidiabetes drug treatment, insulin glargine, and, in obese patients, human premix. An increase in minor hypoglycemia with BIAsp 30 relative to basal insulin has been reported in T2DM patients, but major and nocturnal hypoglycemia rates are generally low. Findings from RCTs in T2DM patients are supported by large observational studies. In summary, BIAsp 30 once to three times daily represents a simple and effective tool for the modern management of diabetes

Topics: Review
Publisher: Dove Medical Press
OAI identifier: oai:pubmedcentral.nih.gov:3048020
Provided by: PubMed Central

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.

Suggested articles

Citations

  1. (2007). A double-blind randomized study comparing the effects of continuing or not continuing rosiglitazone + metformin therapy when starting insulin therapy in people with Type 2 diabetes. Diabet Med.
  2. (2009). Addition of biphasic insulin aspart 30 to optimized metformin and pioglitazone treatment of type 2 diabetes mellitus: The ACTION Study (Achieving Control Through Insulin plus Oral ageNts). Diabetes Obes Metab.
  3. Advancing therapy in type 2 diabetes mellitus with early, comprehensive progression from oral agents to insulin therapy. Clin Ther.
  4. AJ; on behalf of the INITIATE Study Group. Basal insulin or premix analogue therapy in type 2 diabetes patients.
  5. American Diabetes Association. Standards of medical care
  6. Association of glycemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study.
  7. (2008). Association. Economic costs of diabetes in the US in 2007. Diabetes Care.
  8. (2006). Attainment of glycemic goals in type 2 diabetes with once-, twice-, or thrice-daily dosing with biphasic insulin aspart 70/30 (The 1–2–3 study). Diabetes Obes Metab.
  9. Basal insulin supplementation in Type 1 diabetic children: a long-term comparative observational study between continuous subcutaneous insulin infusion and glargine insulin.
  10. (2006). Biphasic insulin aspart 30 plus metformin: an effective combination in type 2 diabetes. Diabetes Obes Metab.
  11. (2008). Biphasic insulin aspart 30 three times daily is more effective than a twice-daily regimen, without increasing hypoglycemia, in Chinese subjects with type 2 diabetes inadequately controlled on oral antidiabetes drugs. Diabetes Care.
  12. (2008). Biphasic insulin aspart 30 treatment improves glycemic control in patients with type 2 diabetes in a clinical practice setting: experience from the PRESENT study. Diabetes Obes Metab.
  13. (2008). Biphasic insulin aspart 30 treatment in patients with type 2 diabetes poorly controlled on prior diabetes treatment: results from the PRESENT study. Curr Med Res Opin.
  14. (2006). Biphasic insulin aspart vs human insulin in adolescents with type 1 diabetes on multiple daily insulin injections. Pediatr Diabetes.
  15. (2006). Comparative efficacy of glimepiride and/or metformin with insulin in type 2 diabetes. Diabetes Res Clin Pract.
  16. (2009). Comparison of insulin analogue regimens in people with type 2 diabetes mellitus in the PREFER Study: a randomized controlled trial. Diabetes Obes Metab.
  17. Comparison of the pharmacokinetics and pharmacodynamics of biphasic insulin aspart and insulin glargine in people with type 2 diabetes.
  18. Continuous subcutaneous insulin infusion versus multiple daily insulin injections in patients with diabetes mellitus: systematic review and meta-analysis.
  19. (2008). E; on behalf of the Danish BIAsp Study Group. Initiating or Switching to Biphasic Insulin Aspart 30/70 Therapy in Subjects with Type 2 Diabetes Mellitus. An Observational Study. Rev Diabet Stud.
  20. (2005). Efficacy and safety of biphasic insulin aspart 30 combined with pioglitazone in type 2 diabetes poorly controlled on glibenclamide (glyburide) monotherapy or combination therapy: an 18-week, randomized, open-label study. Clin Ther.
  21. (2009). Endothelial dysfunction in diabetes: from mechanisms to therapeutic targets. Curr Med Chem.
  22. Epidemiologic studies on the pathogenesis of non-insulindependent diabetes mellitus (NIDDM).
  23. (2005). FlexPen: addressing issues of confidence and convenience in insulin delivery. Clin Ther.
  24. (2002). for the UK. Prospective Diabetes Study Group. Sulfonylurea inadequacy: Efficacy of addition of insulin over 6 years in patients with type 2 diabetes in the UK. Prospective Diabetes Study (UKPDS 57). Diabetes Care.
  25. (2004). Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care.
  26. Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS)
  27. (2005). Guidelines Task Force. Global guideline for Type 2 diabetes. Brussels: International Diabetes Federation,
  28. (2000). Healthrelated quality of life in type 2 diabetes (TARDIS-2). Value Health.
  29. (2002). Immune responses to insulin aspart and biphasic insulin aspart in people with type 1 and type 2 diabetes. Diabetes Care.
  30. Impact of insulin antibodies on insulin aspart pharmacokinetics and pharmacodynamics after 12-week treatment with multiple daily injections of biphasic insulin aspart 30 in patients with type 1 diabetes.
  31. Importance of observational studies in clinical practice. Clin Ther. 2007;29 Spec no:1284–1292.
  32. IMPROVE Study Group Expert Panel. The IMPROVE study – a multinational, observational study in type 2 diabetes: baseline characteristics from eight national cohorts.
  33. (2002). Improved postprandial glycemic control with biphasic insulin aspart relative to biphasic insulin lispro and biphasic human insulin in patients with type 2 diabetes. Diabetes Care.
  34. (2005). INITIATE Study Group. Initiating insulin therapy in type 2 Diabetes: a comparison of biphasic and basal insulin analogs. Diabetes Care.
  35. (2008). Initiating insulin therapy in type 2 diabetes: benefits of insulin analogs and insulin pens. Diabetes Technol Ther.
  36. (1999). Insulin analogs with improved pharmacokinetic profiles. Advanced Drug Delivery Reviews.
  37. (1997). Insulin aspart in a 30/70 premixed formulation. Pharmacodynamic properties of a rapid-acting insulin analog in stable mixture. Diabetes Care.
  38. (1999). Insulin secretagogues: old and new. Diabetes Reviews.
  39. Intensive insulin therapy today: ‘basal-bolus’ using multiple daily injections or CSII? Diabetes Metab.
  40. Long-term efficacy and safety of biphasic insulin aspart in patients with type 2 diabetes.
  41. (2009). Long-term hyperglycemia impairs vascular smooth muscle cell function in women with type 1 diabetes mellitus. Diab Vasc Dis Res.
  42. (2006). Multiple mealtime administration of biphasic insulin aspart 30 versus traditional basalbolus human insulin treatment in patients with type 1 diabetes. Diabetes Obes Metab.
  43. (2009). Nutrition interventions for the prevention of type 2 diabetes.
  44. (2007). OM; BIAsp-3021 study group. Adding biphasic insulin aspart 30 once or twice daily is more efficacious than optimizing oral antidiabetic treatment in patients with type 2 diabetes. Diabetes Obes Metab.
  45. Pharmacokinetics and pharmacodynamics of a premixed formulation of soluble and protamine-retarded insulin aspart.
  46. (2001). Physiological insulin replacement in type 1 diabetes mellitus. Exp Clin Endocrinol Diabetes.
  47. Postprandial glycemic control with biphasic insulin aspart in patients with type 1 diabetes.
  48. (2002). Premixed insulin aspart 30 vs premixed human insulin 30/70 twice daily: a randomized trial in Type 1 and Type 2 diabetic patients. Diabet Med.
  49. (2007). Premixed insulin treatment for type 2 diabetes: analogue or human? Diabetes Obes Metab.
  50. Progression to type 2 diabetes characterized by moderate then rapid glucose increases.
  51. Prospective Diabetes Study Group. UK prospective diabetes study 16. Overview of 6 years’ therapy of type II diabetes: a progressive disease.
  52. (2006). Starting insulin therapy in type 2 diabetes: twice-daily biphasic insulin Aspart 30 plus metformin versus once-daily insulin glargine plus glimepiride. Exp Clin Endocrinol Diabetes.
  53. Starting patients with type 2 diabetes on insulin therapy using once-daily injections of biphasic insulin aspart 70/30, biphasic human insulin 70/30, or NPH insulin in combination with metformin.
  54. Summarising the use of thiazolidinediones with insulin.
  55. Switching to NovoMix® 30 (BIAsp 30) improves glycemic control in patients with type 2 diabetes previously treated with insulin: subgroup analysis from the IMPROVETM study. Diabetes. 2008;57(Suppl 1):A592.
  56. (1998). The genetic basis of type 2 diabetes mellitus: impaired insulin secretion versus impaired insulin sensitivity. Endocr Rev.
  57. (2007). Transferring type 2 diabetes patients with uncontrolled glycemia from biphasic human insulin to biphasic insulin aspart 30: experiences from the PRESENT study. Curr Med Res Opin.
  58. (2002). Twice-daily biphasic insulin aspart 30 versus biphasic human insulin 30: a double-blind crossover study in adults with type 2 diabetes mellitus. Clin Ther.
  59. (2001). Type 1 diabetes: new perspectives on disease pathogenesis and treatment. Lancet.
  60. (2007). Using continuous glucose monitoring to measure the frequency of low glucose values when using biphasic insulin aspart 30 compared with biphasic human insulin 30: a double-blind crossover study in individuals with type 2 diabetes. Diabetes Care.
  61. When glycemic targets can no longer be achieved with basal insulin in type 2 diabetes, can simple intensification with a modern premixed insulin help? Results from a subanalysis of the PRESENT study.
  62. Writing Team for the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group. Effect of intensive therapy on the microvascular complications of type 1 diabetes mellitus.